Sample requirements

Myeloid Gene panel analysis

by Next Generation Sequencing

2-3 mL EDTA-anticoagulated bone marrow / or 4 mL EDTA-anticoagulated peripheral blood

Up to 21 calendar days

Acute Myeloid Leukaemia (AML) – rapid analysis testing

FLT3 ITD/TKD

NPM1

Up to 5 calendar days for FLT3

Up to 14 calendar days for NPM1

NPM1 screening is usually performed in parallel with FLT3, therefore the TAT may be shorter.

Acute Myeloid Leukaemia (AML) –fusion detection and MRD monitoring

NPM1

CBFβ-MYH11 inv(16)

AML1-ETO t(8;21)

Up to 14 calendar days

For clinical urgency based upon priority clinical needs, a request can be made, and a 1 week turn around time arranged with the Lab.

APL – fusion detection and MRD monitoring

PML-RARA t(15;17)

15-20 mL EDTA-anticoagulated peripheral blood and 2-3 mL EDTA-anticoagulated bone marrow

Up to 14 calendar days

For clinical urgency based upon priority clinical needs, a request can be made, and a 1 week turn around time arranged with the Lab

CML and ALL – fusion detection and MRD monitoring

BCR-ABL t(9;22)

BCR-ABL kinase domain mutation analysis

15-20 mL EDTA-anticoagulated peripheral blood and / or 2-3 mL EDTA-anticoagulated bone marrow when required

Same as above.

Please note: A separate sample is not required if MRD monitoring and AKD analysis are requested together.

Up to 14 calendar for CML and ALL*

For clinical urgency based upon priority clinical needs, a request can be made, and a 1 week turn around time arranged with the Lab.

*Please note if BCR-ABL major negative, and where indicated, reflex testing for BCR-ABL minor will be performed.  This may increase the quoted TAT .

Up to 21 calendar days

For clinical urgency based upon priority clinical needs, a request can be made, and a shorter turn around time arranged with the Lab.

Myeloproliferative neoplasms

PV, ET and IMF

MPN panel (JAK2, CALR, MPL)

4 mL EDTA-anticoagulated peripheral blood

Up to 21 calendar days

For clinical urgency based upon priority clinical needs, a request can be made, and a shorter turn around time arranged with the Lab.

B and T Cell clonality analysis

Immunoglobulin and T cell receptor clonality analysis

Formalin fixed parafin embedded tissue (5×10µM scrolls).

For peripheral blood screen 4 mL EDTA PB or a bone marrow aspirate screen 2-3 mL EDTA BM

Up to 14 calendar days

Lymphoid Gene Panel Analysis

by Next Generation Sequencing,

including MYD88 for Waldenstrom’s Macroglobulinaemia (WM)

2-3 mL EDTA-anticoagulated bone marrow / or 4 mL EDTA-anticoagulated peripheral blood

Formalin fixed parafin embedded tissue (5×10µM scrolls).

Up to 21 calendar days

Chronic Lymphocytic Leukaemia (CLL)

IGH Somatic Hypermutation analysis  (IGHV mutation analysis)

CLL gene panel analysis including TP53

2-3 mL EDTA-anticoagulated bone marrow / or 4 mL EDTA-anticoagulated peripheral blood

Same as above.

Please note: A separate sample is not required if IGHV and gene panel analysis are requested together unless FFPE is sent for lymphoid panel testing.

Up to 21 calendar days

Up to 21 calendar days

Hairy Cell Leukaemia (HCL)

BRAF V600E mutation analysis

2-3 mL EDTA-anticoagulated bone marrow / or 4 mL EDTA-anticoagulated peripheral blood

Up to 21 calendar days

SNP array testing

2-3 mL EDTA-anticoagulated bone marrow / or 4 mL EDTA-anticoagulated peripheral blood

(note for Manchester patients this should be sent to the GLH at St Mary’s Hospital; for Liverpool patients please send to the genomics dept at Liverpool Women’s Hospital)

Whole Genome sequencing (WGS)

https://mft.nhs.uk/nwglh/test-information/cancer/solid-tumour/whole-genome-sequencing-for-cancer/